Search
CLPT · Company research

ClearPoint Neuro, Inc. (CLPT): Stock News & Events

Recent company-linked news records available in the database.

Main stock researchCompare stocks
RESEARCH CONTEXT

Understand the numbers

Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.

19records availableHealthcare

Stock News & Events data

Database-backed records only

19 rows
titlesummaryurlsourcepublished atsentimentsentiment scorerelevance score
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPTPomerantz LLP is investigating potential securities fraud claims against ClearPoint Neuro following a significant stock price decline. On September 29, 2026, development partner uniQure announced that their joint treatment for Huntington's disease failed to achieve statistical significance on a primary clinical measure at 48 months, causing ClearPoint's stock to plummet 23.12% to $11.77 per share.View source ↗GlobeNewswire Inc.Oct 13, 2026bearish-11
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPTPomerantz LLP is investigating potential securities fraud claims against ClearPoint Neuro following a significant stock price decline. On September 29, 2026, development partner uniQure announced that their joint treatment for Huntington's disease failed to achieve statistical significance on a primary clinical measure at 48 months, causing ClearPoint's stock to plummet 23.12% to $11.77 per share.View source ↗GlobeNewswire Inc.Oct 13, 2026bearish-11
AngioDynamics (ANGO) Reports Q1 Loss, Lags Revenue EstimatesAngioDynamics reported a quarterly loss of $0.04 per share, beating consensus estimates of $0.10 loss by 60%, but missed revenue expectations with $80.92 million versus the estimated $81.85 million. The medical device company has a Zacks Rank #3 (Hold) rating with mixed estimate revisions. The Medical-Instruments industry ranks in the top 39% of Zacks industries.View source ↗Zacks Investment ResearchOct 8, 2026neutral01
AngioDynamics (ANGO) Reports Q1 Loss, Lags Revenue EstimatesAngioDynamics reported a quarterly loss of $0.04 per share, beating consensus estimates of $0.10 loss by 60%, but missed revenue expectations with $80.92 million versus the estimated $81.85 million. The medical device company has a Zacks Rank #3 (Hold) rating with mixed estimate revisions. The Medical-Instruments industry ranks in the top 39% of Zacks industries.View source ↗Zacks Investment ResearchOct 8, 2026neutral01
Understanding Momentum Shifts in (CLPT) - Stock Traders DailyUnderstanding Momentum Shifts in (CLPT) Stock Traders DailyView source ↗Stock Traders DailyOct 4, 2026neutral00.6
319 shares go to director Timothy T. Richards as fee payment from ClearPoint Neuro (CLPT). - Stock Titan319 shares go to director Timothy T. Richards as fee payment from ClearPoint Neuro (CLPT). Stock TitanView source ↗Stock TitanOct 2, 2026neutral00.6
ClearPoint Neuro Inc (CLPT) Stock Up 3.7% and Still Undervalued -- GF Score: 75/100 - GuruFocusClearPoint Neuro Inc (CLPT) Stock Up 3.7% and Still Undervalued -- GF Score: 75/100 GuruFocusView source ↗GuruFocusOct 1, 2026neutral00.6
$CLPT Stock Is Down 22% Today. Here's What We See in Our Data. - Moomoo$CLPT Stock Is Down 22% Today. Here's What We See in Our Data. MoomooView source ↗MoomooSep 29, 2026neutral00.6
$CLPT stock is down 22% today. Here's what we see in our data. - Quiver Quantitative$CLPT stock is down 22% today. Here's what we see in our data. Quiver QuantitativeView source ↗Quiver QuantitativeSep 29, 2026neutral00.6
ClearPoint Neuro (NasdaqCM:CLPT) Stock Forecast & Analyst Predictions - Simply Wall StreetClearPoint Neuro (NasdaqCM:CLPT) Stock Forecast & Analyst Predictions Simply Wall StreetView source ↗Simply Wall StreetSep 29, 2026neutral00.6
$CLPT stock is down 22% today. Here's what we see in our data. - Quiver Quantitative$CLPT stock is down 22% today. Here's what we see in our data. Quiver QuantitativeView source ↗Quiver QuantitativeSep 29, 2026neutral00.6
ClearPoint Neuro (CLPT) Stock Sees Fair Value Cut As Analysts Factor In Heavier Investment - Yahoo FinanceClearPoint Neuro (CLPT) Stock Sees Fair Value Cut As Analysts Factor In Heavier Investment Yahoo FinanceView source ↗Yahoo FinanceSep 4, 2026neutral00.6
ClearPoint Neuro: Regulatory Momentum Strengthens The Long-Term Investment Case (CLPT) - Seeking AlphaClearPoint Neuro: Regulatory Momentum Strengthens The Long-Term Investment Case (CLPT) Seeking AlphaView source ↗Seeking AlphaAug 4, 2026neutral00.6
ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Misses Revenue Estimates - Yahoo FinanceClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Misses Revenue Estimates Yahoo FinanceView source ↗Yahoo FinanceAug 3, 2026neutral00.6
Why I've (Reluctantly) Sold My ClearPoint Neuro Position (NASDAQ:CLPT) - Seeking AlphaWhy I've (Reluctantly) Sold My ClearPoint Neuro Position (NASDAQ:CLPT) Seeking AlphaView source ↗Seeking AlphaJul 13, 2026neutral00.6
CLPT Forecast — Price Target — Prediction for 2027 - TradingViewCLPT Forecast — Price Target — Prediction for 2027 TradingViewView source ↗TradingViewJun 25, 2026neutral00.6
ClearPoint Neuro (CLPT) Surges 26.0%: Is This an Indication of Further Gains? - Yahoo FinanceClearPoint Neuro (CLPT) Surges 26.0%: Is This an Indication of Further Gains? Yahoo FinanceView source ↗Yahoo FinanceJun 18, 2026neutral00.6
ClearPoint Neuro stock surges on peer’s FDA approval plan - Investing.comClearPoint Neuro stock surges on peer’s FDA approval plan Investing.comView source ↗Investing.comJun 17, 2026neutral00.6
ClearPoint Neuro, Inc. (CLPT) Stock Price: Oct 8 Close $10.49 - GotradeClearPoint Neuro, Inc. (CLPT) Stock Price: Oct 8 Close $10.49 GotradeView source ↗GotradeJan 9, 2026neutral00.6

Informational research only, not financial advice. Forecasts are uncertain and can be wrong.